Core Viewpoint - The company plans to issue a total of 24.2 million new H-shares at a price of HKD 14.50 per share, representing a discount of approximately 12.97% from the closing price of HKD 16.66 on October 8, 2025 [1] Fundraising Details - The total estimated gross proceeds from the placement are approximately HKD 350.9 million, with net proceeds estimated at around HKD 345 million [1] - The net proceeds will be allocated as follows: - Approximately 40% for funding the research and development of IMM2510 and IMM27M for the treatment of solid tumors - Approximately 20% for funding the research and development of IMM01 (Tideglusib) - Approximately 10% for funding the research and development of IMM0306 - Approximately 30% for supplementing the company's working capital and general corporate purposes [1]
宜明昂科-B拟配售2420万股 净筹约3.45亿港元